Here we report a comprehensive serological metabolomic profiling using a well-characterized cohort of PLA2G6-associated young-onset dystonia–parkinsonism patients and matched controls with the aim to describe metabolic features and identify potential biomarkers for the PLA2G6 mutations and severity of clinical symptoms. This evidence concerns the gene PLA2G6 and Parkinsonism.